Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Cloppenburg – page 2

191 clinical trials in Cloppenburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Cloppenburg at a glance
191
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

191 trials in Cloppenburg

Open in trial search

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Randomized trial of irinotecan drug combination versus standard therapy as first-line treatment in patients with locally advanced or metastatic small bowel adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BeOne Medicines I GmbH

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TRI-611
  • Sponsor:Triana Biomedicines Inc.

Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Cloppenburg

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on hyperlipoproteinemia and cardiovascular disease management through advanced therapeutic approaches. Research evaluates long-term safety and effectiveness of treatments for patients requiring lipoprotein apheresis.

  • Lipid Management
  • Cardiovascular Disease Prevention
  • Therapeutic Safety Assessment

These trials aim to improve treatment options for patients with elevated lipoprotein levels and established cardiovascular conditions.

02 Nephrology Studies

Groundbreaking research investigating treatments for IgA Nephropathy, focusing on preventing progressive loss of renal function. The studies evaluate novel therapeutic approaches for managing proteinuria in affected patients.

  • Renal Function Protection
  • Proteinuria Management
  • Disease Progression Prevention

Clinical investigations aim to advance treatment options for patients with kidney disorders through targeted therapeutic approaches.

03 Treatment Optimization

Comprehensive evaluation of therapeutic interventions across multiple medical conditions, with a focus on long-term safety profiles and treatment effectiveness. Studies include both controlled trials and extension phases.

  • Long-term Safety Monitoring
  • Treatment Tolerability
  • Patient Outcomes Assessment

Research efforts are directed at optimizing treatment protocols and improving patient care standards.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.